Contact
QR code for the current URL

Press release Box-ID: 851975

Ypsomed AG Brunnmattstrasse 6 3401 Burgdorf, Switzerland http://www.ypsomed.com
Contact Mr Benjamin Overney +41 34 424 41 59
Company logo of Ypsomed AG
Ypsomed AG

Ypsomed expands to more countries

(PresseBox) ( Burgdorf, )
Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.

Following the successful and controlled launch of the mylife™ YpsoPump® during 2016 in Germany, the Netherlands and the UK, the Management of the Ypsomed Group has decided in favour of geographic expansion. In addition to the existing home markets such as France, Italy, Switzerland, Austria and Scandinavia, the innovative insulin pump is also to be launched in Belgium, Spain and India during 2017. The mylife™ YpsoPump® is already available in Czechia since January 2017, where the subsidiary was established at the end of 2016, mainly for its distribution.

Ypsomed CEO Simon Michel justifies the investment into geographic expansion as follows: "The introduction phase of the mylife™ YpsoPump® has shown that it meets the needs of many people with diabetes. Simplicity in training and in use gives many people a certain degree of freedom and independence in their daily therapy and considerably simplifies the process in the pump centres and physicians practices. Furthermore, the competitive situation in the market for insulin pumps is extremely dynamic. Due to this development we foresee excellent opportunities of growing successfully in this highly competitive market and to continue establishing ourselves as a diabetes specialist. All good reasons to exploit important and missing markets inside and outside Europe with additional investments."

Ypsomed AG

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1'300 employees. Additional information are available under www.ypsomed.com.

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2022, All rights reserved

The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.